Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$4.58.

  • Beam Therapeutics' EPS (Weighted Average and Diluted) rose 5.98% to -$1.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.43, marking a year-over-year decrease of 180.38%. This contributed to the annual value of -$4.58 for FY2024, which is 166.28% down from last year.
  • Beam Therapeutics' EPS (Weighted Average and Diluted) amounted to -$4.58 in FY2024, which was down 166.28% from -$1.72 recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' EPS (Weighted Average and Diluted) peaked at -$1.72 during FY2023, and registered a low of -$5.77 during FY2021.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$4.13 (2022), whereas its average is -$3.48.
  • In the last 5 years, Beam Therapeutics' EPS (Weighted Average and Diluted) spiked by 70.18% in 2020 and then plummeted by 166.28% in 2024.
  • Over the past 5 years, Beam Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$4.19 in 2020, then plummeted by 37.71% to -$5.77 in 2021, then climbed by 28.42% to -$4.13 in 2022, then skyrocketed by 58.35% to -$1.72 in 2023, then crashed by 166.28% to -$4.58 in 2024.